Symbols

INDP

Indaptus·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 3

Gap Down

Bearish Abandoned Baby

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INDP

Indaptus Therapeutics, Inc.

A pharmaceutical company that develops therapy based on the hypothesis that efficient actiation of both innate and adaptive immune cells

Industry

Pharmaceutical

Established Date

02/24/2021

Listing Date

08/04/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.indaptusrx.com

Security Type

Common stock

Office address

3 Columbus Circle, 15th Floor, New York, NY 10019

Business

Introduction

Indaptus Therapeutics, Inc., was incorporated in Delaware on February 24, 2021. The company is a clinical biotechnology company that develops a systemic anticancer and antiviral immunotherapy based on attenuated and inactivated gram-negative bacteria. Its lead drug candidate, Decoy 20, was evaluated in a Phase 1 trial for advanced solid tumors, but further clinical development has been stopped.

Company Financials

EPS

INDP has released its 2025 Q3 earnings. EPS was reported at -2.98, versus the expected -0.2, missing expectations. The chart below visualizes how INDP has performed over recent quarters, highlighting trends in earnings surprises.